Holen Sie sich die Stockscreener-App
83.37
1.92%
1.57
Vorhandelsmarkt:
84.38
1.01
+1.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$81.80
Offen:
$82.81
24-Stunden-Volumen:
5.28M
Relative Volume:
0.75
Marktkapitalisierung:
$106.90B
Einnahmen:
$33.20B
Nettoeinkommen (Verlust:
$4.26B
KGV:
25.34
EPS:
3.29
Netto-Cashflow:
$5.47B
1W Leistung:
+1.21%
1M Leistung:
-7.71%
6M Leistung:
-8.51%
1J Leistung:
+3.48%
1-Tages-Spanne:
$82.50
$83.62
1-Wochen-Bereich:
$81.16
$84.49
52-Wochen-Spanne:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Firmenname
Medtronic Plc
Sektor
Branche
Telefon
01135314381700
Adresse
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Vergleichen Sie MDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-10-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | Bestätigt | Oppenheimer | Perform |
| 2024-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2024-08-14 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Sell |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | Herabstufung | UBS | Buy → Sell |
| 2023-01-09 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-23 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-08-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-06-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-10 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-12-15 | Hochstufung | Goldman | Sell → Neutral |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | Hochstufung | Stifel | Hold → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-05-14 | Herabstufung | DZ Bank | Buy → Hold |
| 2020-03-30 | Herabstufung | Needham | Strong Buy → Buy |
| 2020-03-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Sell |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-06-05 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-27 | Bestätigt | Argus | Buy |
Alle ansehen
Medtronic Plc Aktie (MDT) Neueste Nachrichten
Medtronic: Time To Buy This Dividend Aristocrat Bargain (NYSE:MDT) - Seeking Alpha
Orchestra BioMed Says AVIM Therapy Gets US FDA Breakthrough Device Designation - marketscreener.com
Medtronic: A Dividend Aristocrat With Stability and Innovation - MarketBeat
Wearable Injector Market Future Business Opportunities - openPR.com
Sutures Market Future Business Opportunities 2025-2032 | - openPR.com
Catheters Market Is Booming Worldwide 2025-2032 | Medtronic, ConvaTec, Inc., Hollister Incorporated - openPR.com
Kentuckian Sues Medtronic, FDA Over Spinal Cord Stimulator - Law360
Medtronic Heats CGM Space Up with New FDA Nod - Medical Device and Diagnostic industry
Medtronic continues to close gap in diabetes tech - BioWorld MedTech
Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps - MedTech Dive
Aortic Repair Devices Market Is Booming Worldwide 2025-2032 | Medtronic PLC,Cook Medical,Terumo Corporation - openPR.com
Medtronic nets FDA approval to pair Simplera Sync CGM with MiniMed 780G - Fierce Biotech
Medtronic: One Of The Best Times To Buy (NYSE:MDT) - Seeking Alpha
US FDA approves Medtronic’s new Simplera Sync sensor for the MiniMed 780G system - Pharmabiz.com
Medtronic wins FDA nod for new Simplera Sync CGM with MiniMed 780G - MassDevice
FDA approves Medtronic’s Simplera Sync sensor for MiniMed system - Medical Device Network
Medtronic (NYSE:MDT) Gains FDA Approval for Advanced Insulin Sensor in 2025 - Yahoo
New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved - Medtronic
FDA Approves Revolutionary Diabetes Sensor: Medtronic's New Tech Eliminates Fingersticks, Simplifies Management - Stock Titan
Medtronic (MDT) Stock Dips While Market Gains: Key Facts - Nasdaq
Medtronic (MDT) Faces Tariff Risks Amid Global Trade Changes - GuruFocus
Barclays Flags Medtronic, J&J as Most at Risk from Looming Pharma Tariffs - Yahoo Finance
Medtronic plc (MDT): A Bull Case Theory - Insider Monkey
Spinal Column Market Deep Research Report with Forecast by 2032 | - openPR.com
Tariffs top of mind for medtech firms this earnings season - MedTech Dive
Medtronic: Rock 'n' Roll Dad's New Music Inspired by Son's Diagnosis - Yahoo Finance
Is Now An Opportune Moment To Examine Medtronic plc (NYSE:MDT)? - simplywall.st
Medtronic (MDT) Gains But Lags Market: What You Should Know - Yahoo Finance
Truist Trims Price Target on Medtronic to $90 From $93, Keeps Hold Rating - marketscreener.com
Baird Adjusts Price Target on Medtronic to $94 From $91, Maintains Neutral Rating - MarketScreener
Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights - GlobeNewswire Inc.
Medtronic Becomes Oversold - Nasdaq
Medtronic's MiniMed 780G Leads in Time in Target Range for Type 1 Diabetes - Medical Device and Diagnostic industry
Citigroup Adjusts Medtronic Price Target to $103 From $107, Maintains Buy Rating - MarketScreener
Looking Into Medtronic's Recent Short Interest - Benzinga
Medtronic PLC (MDT) Shares Gap Down to $84.31 on Apr 4 - GuruFocus
Piper Sandler maintains Medtronic stock neutral with $90 target By Investing.com - Investing.com UK
Medtronic (MDT) Stock Moves -1.09%: What You Should Know - Nasdaq
May 23rd Options Now Available For Medtronic (MDT) - Nasdaq
Boston Scientific’s Farapulse matches Medtronic cryoablation in trial - MedTech Dive
Medtronic (MDT) Advances But Underperforms Market: Key Facts - Yahoo Finance
Former Medtronic CEO Criticizes RFK Jr.'s HHS Leadership - Medical Device and Diagnostic industry
Medtronic, Recor commence hostilities over RDN patents - BioWorld MedTech
3 takeaways from ACC 2025 - MedTech Dive
Evercore ISI Adjusts Medtronic Price Target to $105 From $104, Maintains Outperform Rating - MarketScreener
Boston Scientific’s Farapulse Triumphs Over Medtronic’s Artic Front in Atrial Fibrillation Trial - Medical Device and Diagnostic industry
The Zacks Analyst Blog Highlights Mastercard, Medtronic, HCA Healthcare and United Homes - Nasdaq
Medtronic plc (NYSE:MDT) Stake Boosted by Geode Capital Management LLC - MarketBeat
Medtronic Breaks Out Strong TAVR Data at ACC - Medical Device and Diagnostic industry
Top Stock Reports for Mastercard, Medtronic & HCA Healthcare - MSN
Medtronic (NYSE:MDT) TAVR System Shows Strong Five-Year Performance Despite 3% Price Dip - Yahoo
Finanzdaten der Medtronic Plc-Aktie (MDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):